White Paper: US Biosimilars 2018: Opportunities and Challenges

As we start a new year, we would like to share Back Bay’s latest thought piece, US Biosimilars: Opportunities and Challenges. Researched and written by Michelle Hoffmann, PhD and Jon Barry, MD, the insights are substantive, with calculated optimism.